Subfoveal Choroidal Thickness and Visual Acuity After Intravitreal Injection of Ranibizumab in Diabetic Retinopathy

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

February 1, 2023

Study Completion Date

February 1, 2023

Conditions
Subfoveal Choroidal ThicknessIntravitrealRanibizumabVisual AcuityDiabetic Retinopathy
Interventions
PROCEDURE

Intravitreal injection of ranibizumab

"These patients were received three intravitreal injection of ranibizumab with one month interval. 3D-OCT by enhanced depth spectral-domain imaging (EDI-OCT) was done preoperative and a month after every injection.~All patients recieved topical anesthesia as 0.5 mg/0.05 ml , ranibizumab is injected 4 mm (3.5 mm in Pseudophakia) from the limbus intravitreally (in the lower temporal quadrant) by a needle (27gauge)."

Trial Locations (1)

Unknown

Al-Azhar University, Asyut

All Listed Sponsors
lead

Egyptian Biomedical Research Network

NETWORK

NCT06173245 - Subfoveal Choroidal Thickness and Visual Acuity After Intravitreal Injection of Ranibizumab in Diabetic Retinopathy | Biotech Hunter | Biotech Hunter